NASDAQ:DXR Daxor Q2 2025 Earnings Results & Report $8.10 -0.25 (-2.99%) Closing price 03:49 PM EasternExtended Trading$8.07 -0.03 (-0.31%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Daxor reported Q2 2025 earnings on March 2, 2026. The company reported EPS of -$0.1010. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateMarch 2, 2026TimeBefore Market Opens Daxor EPS ResultsActual EPS-$0.1010Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADaxor Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Daxor Q2 2025 Earnings FAQ Did Daxor beat earnings estimates for Q2 2025? Daxor (NASDAQ:DXR) reported earnings of -$0.1010 per share for Q2 2025. The report was announced on Monday, March 2, 2026. Daxor Earnings HeadlinesDaxor Expands Midwest Footprint with Launch of ezBVA Lab Program at Premier Kansas Academic Medical CenterNovember 17 at 12:16 PM | finance.yahoo.comDaxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26October 15, 2026 | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 17 at 1:00 AM | Porter & Company (Ad)Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026October 14, 2026 | globenewswire.comDaxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026October 13, 2026 | globenewswire.comDaxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026October 1, 2026 | globenewswire.comSee More Daxor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email. Email Address About DaxorDaxor (NASDAQ:DXR) is a medical technology company focused on blood-volume measurement and personalized blood management. Founded in 1970, the company develops diagnostic tools intended to help clinicians assess a patient’s blood volume and support treatment decisions. Its flagship product, the BVA-100 Blood Volume Analyzer, is an FDA-cleared system that measures total blood volume as well as red blood cell and plasma volumes. The system is designed for use in clinical settings, where these measurements can help inform care for patients with conditions such as heart failure and other fluid-management challenges. Daxor’s products and related services are directed primarily at healthcare providers and medical institutions. The company’s work centers on making blood-volume analysis available as a clinical tool to support individualized patient care.View Daxor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.